Lenvatinib and Pembrolizumab to Treat Patients With Anal or Rectum Cancer That Has Gotten Worse After Initial Treatment

• Status: NOT_YET_RECRUITING
• Trial end date: 2029-03-26

Summary

The purpose of this study is to gather information on the safety and effectiveness of lenvatinib combined with pembrolizumab in anal/rectal cancer that has spread to other parts of the body and will not respond to standard care.

• Phase: PHASE2

Details

• Lead Sponsor: University of Chicago
• Treatments: lenvatinib; pembrolizumab